Industry
AlvaMed, Inc.
Total Trials
4
Recruiting
0
Active
3
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
Failure Rate
25.0%
1 terminated/withdrawn out of 4 trials
Success Rate
0.0%
-86.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
N/A
4(100.0%)
4Total
N/A(4)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (4)
Showing 4 of 4 trials
NCT04758611Not ApplicableActive Not Recruiting
The ETCHES I Study (Endovascular Treatment of Communicating Hydrocephalus With an Endovascular Shunt)
Role: collaborator
NCT05250505Not ApplicableActive Not Recruiting
Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
Role: collaborator
NCT05232838Not ApplicableActive Not Recruiting
US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
Role: collaborator
NCT05501002Not ApplicableTerminated
Pilot Study to Evaluate the CereVasc® EShunt® System in the Treatment of Communicating Hydrocephalus
Role: collaborator
All 4 trials loaded